Jaguar Animal Health (NASDAQ:JAGX) Releases Quarterly Earnings Results

Jaguar Animal Health (NASDAQ:JAGX) posted its earnings results on Wednesday. The biotechnology company reported ($15.70) EPS for the quarter, topping the consensus estimate of ($52.15) by $36.45, Zacks reports. The firm had revenue of $1.23 million for the quarter, compared to the consensus estimate of $4.24 million.

Here are the key takeaways from Jaguar Animal Health’s conference call:

• Rare-disease focus and clinical catalysts: Jaguar is concentrating its human-health development efforts entirely on crofelemer for intestinal failure, with the MVID clinical package expected by the end of 2026, a potential NDA filing in mid-2027, and possible U.S. approval by late 2027 if breakthrough therapy designation is granted.
• Encouraging proof-of-concept data: Long-term treatment was associated with parenteral-support reductions of up to 48% in an MVID patient and up to 40% in SBS-IF patients, with relapse after treatment withdrawal and no reported crofelemer-related safety issues.
• Non-dilutive funding and partnering strategy: The Future Pak agreement provided $18 million in upfront payments, with up to $17 million in additional potential milestones, while Jaguar continues manufacturing the licensed products and is seeking a larger partner for its intestinal-failure program.
• Financial losses and revenue pressure remain significant: Second-quarter prescription-product revenue fell 60% year over year to approximately $1.2 million, net loss attributable to common shareholders widened to $12.7 million, and losses from debt extinguishment and fair-value adjustments increased.
• Animal-health expansion planned: Jaguar expects to launch Neonorm Dog through online and retail channels, including Amazon and Chewy, leveraging relationships developed through its former Canalevia-CA1 commercialization efforts.

Jaguar Animal Health Trading Down 5.3%

NASDAQ JAGX opened at $0.92 on Thursday. Jaguar Animal Health has a 1 year low of $0.72 and a 1 year high of $85.40. The company has a market cap of $554,580.00, a PE ratio of -0.00 and a beta of -0.06. The stock’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $9.34.

Wall Street Analysts Forecast Growth

JAGX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. Wall Street Zen raised Jaguar Animal Health from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to MarketBeat, Jaguar Animal Health currently has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.